CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $793 | -40.8% | 28,830 | -27.0% | 0.04% | -36.2% |
| Q2 2023 | $1,340 | +57.6% | 39,480 | +67.0% | 0.06% | +45.0% |
| Q1 2023 | $850 | +129.7% | 23,636 | +185.0% | 0.04% | +100.0% |
| Q4 2022 | $370 | -99.9% | 8,293 | -64.0% | 0.02% | -48.7% |
| Q3 2022 | $647,000 | +27.4% | 23,033 | +22.2% | 0.04% | +2.6% |
| Q2 2022 | $508,000 | +6.7% | 18,845 | +34.8% | 0.04% | +22.6% |
| Q1 2022 | $476,000 | +71.2% | 13,985 | +94.6% | 0.03% | -11.4% |
| Q4 2021 | $278,000 | -36.8% | 7,185 | -11.9% | 0.04% | -40.7% |
| Q3 2021 | $440,000 | +129.2% | 8,155 | -25.7% | 0.06% | +7.3% |
| Q4 2020 | $192,000 | -71.3% | 10,980 | -75.6% | 0.06% | -74.1% |
| Q3 2020 | $668,000 | – | 45,070 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |